# 1. Financial Performance ## A. Key Figures * **Q3 Revenue:** ₹633 Cr (+13.4%) · ₹618 Cr ex-fertility (+8% vol.) * **9M Revenue:** ₹1,893 Cr (+16%) · **Adj. EBITDA:** ₹346 Cr (+20%) · **Margin:** 18.3% (+60 bps) * **Q3 Adj. EBITDA:** ₹111 Cr (+20%) · **Margin:** 17.5% (flat YoY) * **Net Debt:** ₹680 Cr (Sep) · **Proj. Pre-Ind AS EBITDA:** >₹500 Cr (FY26) · **Debt/EBITDA:** <5x * **Govt. Billing (Q3):** ₹25 Cr · **Net Receivables Benefit:** ₹5 Cr ## B. Revenue Growth * **Digital Momentum:** Digital revenue posted strong double-digit growth despite lower paid media, with mobile app scaling rapidly and now contributing a meaningful share. * **Oncology Resilience:** Core oncology demand remained robust, supported by higher patient volumes and improved hospital utilization across mature clusters. * **Growth Drivers:** Revenue expansion fueled by clinical program depth, service diversification, and steady mix of complex cases. ## C. EBITDA Margin * **Margin Stability & Leverage:** EBITDA margins held firm with operating leverage from higher utilization, while value creation initiatives target procurement, conversion, and clinical density gains. * **Case Mix Pressure:** Gross margin compression observed due to shift toward medical oncology, which carries higher pharmacy costs but supports EBITDA through volume leverage. * **ROCE Trajectory:** Pre-tax ROCE at 17% for 9M, with structural upside expected as new centers approach ₹10 Cr/month revenue threshold, unlocking capital efficiency. * **High-Return Assets:** Mature bedded centers generate ~25–26% EBITDA margins and ~30% ROCE, highlighting scalability of established units. ## D. Cash Flow * **Government Collections:** Q3 saw meaningful recovery in government receivables, with ₹25 Cr billed and net ₹5 Cr improvement, easing cash flow pressure post-Andhra strike. ## E. Balance Sheet * **Capital Strengthening:** Rights issue announced to fortify balance sheet; details pending Board approval. * **Debt Coverage:** Projected EBITDA ensures net debt/EBITDA remains below 5x, sufficient to meet Vizag obligations and maintenance capex. --- # 2. Patient Volume & ARPP ## A. Key Figures * **Outpatient Volume Growth:** **26%** YoY · **Inpatient Volume Growth:** **37%** YoY * **YTD Volume Growth:** **16%** YoY (incl. MG Hospital Vizag) * **ARPP (Q3FY26):** **₹84,000** (+5% YoY) * **Campaign-Led Revenue Growth:** **38%** YoY (share rose from 20% to 27%) ## B. Volume Growth * **Resilient Expansion:** Strong double-digit outpatient and inpatient volume growth despite Google Ads disruptions, reflecting improved digital conversion and clinical monetization. * **Growth Moderation:** Underlying volume growth slowed to 11% YoY excluding AP, down from 19% in H1, due to strikes and one-off disruptions. * **Sustained Momentum:** Full-year volume growth supported by successful integration of MG Hospital Vizag, with **8%–10% growth** expected in coming quarters. * **Strategic Metric Discipline:** Company to report only patient volume and ARPP going forward, emphasizing long-term value over operational metrics like bed occupancy. ## C. ARPP Trends * **Pricing & Mix Leverage:** ARPP rose 5% YoY to ₹84,000, driven by favorable case and payor mix shifts, particularly in the South cluster. * **Regional Divergence:** ARPP declined 3% YoY in the East due to government scheme transition in Odisha, though offset by strong volumes. * **Margin Strength:** East and South clusters show robust profitability, with some centers achieving **over 25%–26% EBITDA margins**. ## D. Conversion Efficiency * **Digital Channel Acceleration:** Campaign-led revenue grew at a strong pace and now accounts for **27% of total revenue**, signaling enhanced marketing efficiency and patient acquisition. --- # 3. Cluster & Geography Mix ## A. Key Figures * **West Cluster Revenue Growth:** **17%** YoY (Q3 FY'26) · **11%** Volume Growth * **East Cluster Revenue Growth:** **12%** YoY (Q3 FY'26) · **16%** Volume Growth * **South Cluster Revenue Growth:** **9%** YoY (Q3 FY'26) ## B. West Cluster * **Outperformance in Core Markets:** Strong double-digit revenue and volume growth driven by capacity expansion in Ahmedabad, clinician additions, and targeted marketing in Gujarat and Maharashtra. * **Strategic Expansion Momentum:** Mumbai delivers high-teens growth, validating brownfield expansion plans; cluster-level EBITDA expected to converge with or exceed company average on back of sustained investment. * **Growth Anchored in Established Centres:** Majority of historical growth (80–85% over three years) derived from mature facilities, underscoring operational depth and scalability. ## C. East Cluster * **Robust Volume-Led Growth:** Double-digit revenue expansion supported by strong demand in Cuttack and Ranchi, with Kolkata ramp-up contributing to 16% volume growth. ## D. South Cluster * **Growth Moderated by Transitory Disruptions:** Single-digit revenue growth despite strength in Bangalore and Vizag, weighed down by a market strike in Vizag and temporary scheme-related volume dip in Andhra Pradesh. * **Resilience in Key Hubs:** Bangalore’s strong performance partially offset regional headwinds, reinforcing its role as a Centre of Excellence. --- # 4. Capacity & Utilization ## A. Key Figures * **Bed Capacity Expansion:** **~1,000 new beds** to be added over **3–4 years** (total to ~3,500 beds) * **Utilization Potential:** Network operating at **~60% of revenue potential** * **Project Timeline:** **North Bangalore greenfield project** (120+ beds) on track for **Q4 FY'26 launch**; new centers operational by **FY'27** ## B. Bed Capacity * **Strategic Scalability:** Expansion focused on **Bangalore** as primary growth engine, reinforcing core market dominance and enabling profitable growth. * **Phased Growth Execution:** Capacity increase driven by both **brownfield reconfigurations** (e.g., 20 beds in Bangalore CoE) and **large-scale greenfield builds**. ## C. Utilization Rate * **Significant Embedded Leverage:** Current utilization at ~60% indicates substantial **runway for revenue growth without new capacity**, especially as several centers approach critical scale. * **Maturing Network Effect:** ~50% of centers are 8–10 years old, positioning them for **margin and ROCE expansion** in the medium term. ## D. Greenfield Projects * **Technology-Led Differentiation:** North Bangalore facility to feature **MR-LINAC**—a first in the city—bolstering clinical leadership and service premiumization. * **Core Market Reinforcement:** Two new greenfield projects underway in **Bangalore**, underscoring confidence in regional performance and demand depth. ## E. Brownfield Expansions * **Targeted Footprint Optimization:** Expansions underway across **7–8 high-potential centers**, including **60-bed addition in Cuttack** and incremental increases in Vizag, Kolkata, and Borivali. --- # 5. Clinical & Service Mix ## A. Key Figures * Medical Tourism Revenue: 3.5% of total revenue (current) · 7% target in 4 years * **South Cluster Volume Growth:** **11%** YoY in Q3 FY'26 (excl. Andhra Pradesh) * **Oncology MVT Share:** **25%–30%** of India’s total oncology-related medical value travel ## B. Case Complexity * **Clinical Leadership:** HCG reinforces its core oncology platform by managing high-complexity cases at scale, achieving **clinically superior outcomes** across surgical, medical, and radiation oncology. * **Advanced Capabilities:** Successful treatment of **vision-threatening tumors**, **rare molecular breast cancer**, and **high-risk geriatric surgeries** underscores precision medicine and robotic expertise. * **Growth Leverage:** Underutilized capacity across hospitals supports volume expansion, driven by **high-end medical oncology services** like immunotherapy and CAR-T at the Bangalore Centre of Excellence. ## C. Therapy Performance * **Innovation in Radiation Oncology:** Launched green initiative for sustainability and expanded clinical applications with **low-dose restorative radiotherapy** for non-cancerous conditions. ## D. Medical Tourism * **Strategic Expansion:** Targeted push into **six to seven international markets** with dedicated resources to grow medical tourism, capitalizing on oncology’s dominance in India’s MVT sector. * **Competitive Positioning:** Current low share attributed to **domestic focus** and **non-metro footprint**, with Bangalore as the primary metro gateway for global patients. * **Credibility Boost:** NABH accreditation of K. R. Hospital’s ethics committee strengthens capability in advanced clinical trials and research-led care. --- # 6. Risks & Operational Factors ## A. Key Figures * **Aggregator Dependence:** **9%** current mix (↓ from 12%) * **ROCE:** **28%–30%** achieved in multiple Centres of Excellence ## B. Regional Disruptions * **Operational Impact:** Strike in Andhra Pradesh caused loss of **20–25 working days**, severely disrupting volumes in November; recovery now normalized. ## C. Center Performance & Strategy * **Revenue Quality Improvement:** Reduced reliance on aggregators enhances margin sustainability and long-term earnings resilience. * **Leadership Strengthening:** New regional head appointed for East cluster with **30+ years of local experience** to drive execution and turnaround underperforming centers. * **Network Optimization:** Kolkata and other underperforming centers under active EBITDA review; **material operating leverage potential** exists across sub-optimal units. * **Structural Margin Outlook:** Cancer care hospitals inherently face lower margins due to **equipment intensity and smaller scale**, yet top-tier units demonstrate **near-30% ROCE**, validating high-return potential with improved utilization. --- # 7. Guidance & Outlook ## A. Key Figures * **Growth Guidance:** **15%+** annual (confirmed) · **High-teens CAGR** medium-term aspiration * **Capex:** **₹275–280 Cr** FY26 · **10%–12% higher** in FY27 * **Margin Target:** **23%–24%+ EBITDA** in 3–4 years · **mid-25%** aspirational · **26%–27%** achieved at mature centers ## B. Growth Forecast * **Sustained Momentum:** Structural demand for cancer care outpaces supply, supporting confidence in exceeding **15%+ growth guidance** through capacity expansion and utilization gains. * **Near-Term Strength:** Q4 expected to be strongest of FY26, with North Bangalore Greenfield contributing from Q1 FY27 onward. * **Scalability Levers:** Underutilized existing capacity (60%) provides significant headroom for volume-driven growth without proportional cost increases. ## C. Margin Target * **Clear Path to Margin Expansion:** Target of **23%–24%+ EBITDA margins** supported by scale benefits and **payor/case mix optimization**, with mature centers already delivering **26%–27%**, proving operational model viability. * **Capital-Efficient Growth:** **80% of margin gains** expected from existing centers, underscoring asset-light leverage and operational maturity over new builds. ## D. Capex Plan * **Disciplined Investment:** Capex set to rise **modestly by 10%–12%** in FY27, aligned with phased ramp-up and ROCE improvement goals. * **One-Time Cost:** Founder contract amendment of **₹2 Cr** to impact Q4, not reflected in current results.